OptiPin
Kisspeptin: uses, dosing & the facts
A neuropeptide encoded by the KISS1 gene that acts on the KISS1R receptor (also called GPR54) in the hypothalamus, where it is the upstream trigger for GnRH release and therefore for LH and FSH. Two fragments are used in research: kisspeptin-10, the short active fragment, and kisspeptin-54, the longer form. It is studied in reproductive endocrinology rather than sold as a performance compound. This is an evidence-graded reference – what it is, what it's used for, typical reported dosing, half-life, side effects, and how to track it. It is educational, not medical advice or a recommendation to use a research compound.
- • Kisspeptin – Specialty. A neuropeptide encoded by the KISS1 gene that acts on the KISS1R receptor (also called GPR54) in the hypothalamus, where it is the upstream trigger for GnRH release and therefore for LH and FSH.
- • Commonly used for research into hypothalamic control of the reproductive axis, studied as an ovulation trigger in fertility protocols, investigated in hypothalamic amenorrhoea.
- • Half-life: Short. Kisspeptin-10 clears within minutes; kisspeptin-54 is longer at roughly half an hour. Both are far shorter than the peptides usually dosed weekly..
- • Status: Approved for a specific use · off-label otherwise – an educational reference, not a dose protocol or sourcing advice.
What Kisspeptin is
A neuropeptide encoded by the KISS1 gene that acts on the KISS1R receptor (also called GPR54) in the hypothalamus, where it is the upstream trigger for GnRH release and therefore for LH and FSH. Two fragments are used in research: kisspeptin-10, the short active fragment, and kisspeptin-54, the longer form. It is studied in reproductive endocrinology rather than sold as a performance compound.
What Kisspeptin is used for
- • Research into hypothalamic control of the reproductive axis
- • Studied as an ovulation trigger in fertility protocols
- • Investigated in hypothalamic amenorrhoea
- • Investigated in low sexual desire, where the signal is central rather than hormonal
These are reported/community uses, not proven clinical outcomes. Most research peptides have limited human trial data behind such claims.
Typical reported dosing
| Injectable | Research protocols use intravenous infusion or bolus, dosed per kilogram, under clinical supervision. There is no established subcutaneous self-administration schedule, and the two fragments are not interchangeable at the same dose. |
Presented as commonly-reported patterns for information only – not a dose recommendation. Kisspeptin dosing is a decision for a qualified clinician.
Reconstitution
Supplied as a lyophilised powder. Reconstitute with bacteriostatic water and keep refrigerated. Because the effective research doses are weight-based and given intravenously, a reconstitution chart built for subcutaneous milligram dosing does not transfer. The arithmetic is the same for any peptide: concentration = vial mg ÷ water mL, and on a U-100 syringe 100 units = 1 mL. Compute your own vial with the reconstitution calculator.
Half-life & cycling
Half-life: Short. Kisspeptin-10 clears within minutes; kisspeptin-54 is longer at roughly half an hour. Both are far shorter than the peptides usually dosed weekly.. Half-life drives dosing frequency and how quickly the compound clears – see it plotted on the Kisspeptin half-life calculator.
Cycling
No established cycle. Continuous exposure downregulates the KISS1R receptor and blunts the response, which is the opposite of the intended effect, so research protocols are pulsatile or single-dose rather than daily.
Side effects & warnings
- an injection site that turns red, hot or hard, spreads, weeps, or comes with a fever – same-day medical care – research-grade material carries no sterility guarantee, so abscess and cellulitis are the documented consequence
- swelling of the lips, tongue or throat, trouble breathing, or widespread hives after a dose – emergency care
- an erection lasting more than four hours – emergency care – priapism causes permanent damage untreated
- a mole that is new, changing, or bleeding – a dermatology review before any further dosing
- • Generally well tolerated at research doses
- • Transient flushing or headache reported
- • Receptor downregulation with continuous rather than pulsatile exposure
- • Effects on the reproductive axis are the point of the compound, so they are not a side effect to be dismissed
Not FDA-approved and not a licensed medicine. It acts directly on the hypothalamic-pituitary-gonadal axis, so it can disturb the reproductive axis, menstrual cycle and fertility. Research use only, and not something to self-administer alongside TRT, hCG or a restart protocol without a clinician who is managing the whole axis.
Tracking Kisspeptin in OptiPin
If you're tracking a Kisspeptin protocol, OptiPin logs each dose with reminders and site rotation, charts the outcome you care about over your dose timeline, keeps per-vial inventory with runout warnings, and (where relevant) does the reconstitution math – all on-device, no account.
Log doses, outcomes & vials in OptiPin
Reminders, outcome-over-dose charts, vial runout warnings, and built-in reconstitution math – all on-device.
Download on the App StoreFAQ
What is Kisspeptin?
A neuropeptide encoded by the KISS1 gene that acts on the KISS1R receptor (also called GPR54) in the hypothalamus, where it is the upstream trigger for GnRH release and therefore for LH and FSH. Two fragments are used in research: kisspeptin-10, the short active fragment, and kisspeptin-54, the longer form. It is studied in reproductive endocrinology rather than sold as a performance compound.
What is Kisspeptin used for?
Commonly discussed uses include: research into hypothalamic control of the reproductive axis, studied as an ovulation trigger in fertility protocols, investigated in hypothalamic amenorrhoea, investigated in low sexual desire, where the signal is central rather than hormonal. These are reported uses, not proven outcomes or a recommendation.
How is Kisspeptin dosed?
Commonly reported dosing: Injectable – Research protocols use intravenous infusion or bolus, dosed per kilogram, under clinical supervision. There is no established subcutaneous self-administration schedule, and the two fragments are not interchangeable at the same dose.. This reflects patterns discussed in the community and is presented for information only, not as a dose recommendation – Kisspeptin is not an approved medicine and dosing should involve a qualified clinician.
How do you reconstitute Kisspeptin?
Supplied as a lyophilised powder. Reconstitute with bacteriostatic water and keep refrigerated. Because the effective research doses are weight-based and given intravenously, a reconstitution chart built for subcutaneous milligram dosing does not transfer. On a U-100 syringe, 100 units = 1 mL. Concentrations vary by vial, so compute from your own vial with a reconstitution calculator.
What is Kisspeptin's half-life?
Short. Kisspeptin-10 clears within minutes; kisspeptin-54 is longer at roughly half an hour. Both are far shorter than the peptides usually dosed weekly.. Half-life shapes how often it is dosed and how quickly it clears.
What are Kisspeptin's side effects?
Reported effects include: generally well tolerated at research doses, transient flushing or headache reported, receptor downregulation with continuous rather than pulsatile exposure, effects on the reproductive axis are the point of the compound, so they are not a side effect to be dismissed. Because it is a research compound, its safety profile is not fully characterized; discuss risks with a clinician.
Evidence & further reading
- Search the peer-reviewed literature for Kisspeptin on PubMed (entry point to the primary evidence base, not a specific citation).
- Kisspeptin on ClinicalTrials.gov – registered human trials, if any.
- US FDA / 503A compounding status of research peptides (2026).
- OptiPin peptides guide – categories, evidence grading, and how to run a protocol honestly.
Related
KPV · Melanotan · Oxytocin · Argireline · PT-141 · melanotan-ii · Reconstitution calculator · All peptides